Advertisement

Topics

Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and ...

16:05 EDT 10 Aug 2017 | BioMedReports - Blog

Enrollment in all cohorts of ENCORE 601 have proceeded rapidly. The second stage of the ENCORE 601 cohort enrolling PD-1 (programmed death receptor-1) refractory melanoma

Read more...

Original Article: Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and ...

NEXT ARTICLE

More From BioPortfolio on "Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and ..."

Quick Search
Advertisement
 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...